According to a new report published by Allied Market Research, titled, โ€œAnti-Inflammatory Therapeutics Market, by Drug Class and Indication Type : Global Opportunity Analysis and Industry Forecast, 2021-2028,โ€ the global anti-inflammatory therapeutics market size was $98,026 million in 2020 and is projected to reach $125,552 million by 2028, registering a CAGR of 4.0% from 2021 to 2028.

๐‹๐ข๐ฌ๐ญ ๐จ๐Ÿ ๐Š๐ž๐ฒ ๐๐ฅ๐š๐ฒ๐ž๐ซ๐ฌ :

Some of the key players operating in the anti-Inflammatory Therapeutic market are Pfizer, Inc., Abbvie, Inc., Johnson & Johnson, GlaxoSmithKline, Merck & CO., Inc., Novartis, F. Hoffman, La Roche AG, Eli Lily and Company, AstraZeneca PLC., and Amgen..

๐ƒ๐จ๐ฐ๐ง๐ฅ๐จ๐š๐ ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ

๐Š๐„๐˜ ๐…๐ˆ๐๐ƒ๐ˆ๐๐†๐’ ๐Ž๐… ๐“๐‡๐„ ๐’๐“๐”๐ƒ๐˜

  • North America occupied 36.64% share of the global anti-inflammatory therapeutic market in 2020.
  • By indication, the arthritis segment is anticipated to grow with the highest CAGR throughout the forecast period.
  • By indication, the arthritis segment was the highest contributor to the anti-inflammatory therapeutics market, with $39,481.09 million in 2020, and is estimated to reach $52,952.43 million by 2028, at a CAGR of 4.6% during the forecast period.
  • Depending on drug class, the anti-inflammatory biologics segment accounted for $58,618.54 million in 2020, and is estimated to reach $77,093.85 million by 2028, registering a CAGR of 4.3%.
  • Asia-Pacific is estimated to grow at the highest CAGR of 5.2% during the forecast period.

๐—–๐—ผ๐˜ƒ๐—ถ๐—ฑ-๐Ÿญ๐Ÿต ๐—ฆ๐—ฐ๐—ฒ๐—ป๐—ฎ๐—ฟ๐—ถ๐—ผ:

The impact of COVID-19 pandemic is expected to remain positive for the anti-inflammatory therapeutic market, owing to the inflammation caused by SARS-COV 2. SARS-CoV-2 is a beta coronavirus causing severe anti-inflammatory pneumonia, as COVID-19 can cause severe inflammation to patients diagnosed with it. According to reports, cytokine storm is strongly responsible for death in such patients. Some of the consequences of severe inflammation and cytokine storms include acute respiratory distress syndrome, acute lung injury, and multiple organ dysfunction syndromes, which lead to increase in the research and the development of anti-inflammatory drugs for the treatment of inflammation caused by COVID-19. For example, many clinical trials are currently underway to alleviate this destructive inflammation. One of them is NLRP3 inflammasome, which targets multiple mechanisms associated with COVID-19 excessive inflammation. Thus, such factors have positively impacted the market growth during the global health crisis.

๐…๐จ๐ซ ๐๐ฎ๐ซ๐œ๐ก๐š๐ฌ๐ž ๐ˆ๐ง๐ช๐ฎ๐ข๐ซ๐ฒ

The global anti-inflammatory therapeutics market is segmented into indication, drug class, and region. On the basis of indication, the market is categorized into arthritis, respiratory diseases, multiple sclerosis, psoriasis, anti-inflammatory bowel disease (IBD), and other anti-inflammatory diseases. Arthritis is expected to register the highest CAGR during the forecast period, owing to increase in geriatric population, as it is found to be more prevalent in the geriatric population and cause inflammation in joints.

Depending on drug class, it is fragmented into nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologics. The nonsteroidal anti-inflammatory drugs (NSAIDs) is expected to register the highest CAGR during the forecast period, owing to increase in patient population suffering from chronic disease and unavailability of effective treatments. Moreover, increase in affordability coupled with high healthcare spending and rise in awareness of biologics, especially, in emerging markets are expected to represent a huge market potential for biologics. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

๐—š๐—ฒ๐˜ ๐——๐—ฒ๐˜๐—ฎ๐—ถ๐—น๐—ฒ๐—ฑ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ

๐Ž๐ญ๐ก๐ž๐ซ ๐“๐ซ๐ž๐ง๐๐ข๐ง๐  ๐‘๐ž๐ฉ๐จ๐ซ๐ญ๐ฌ:

Contrast Media Injectors Market

Dialysis Concentrate Market

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โ€œMarket Research Reportsโ€ and โ€œBusiness Intelligence Solutions.โ€ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.


David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975

Leave a comment

Your email address will not be published. Required fields are marked *